Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice

Blood

Volumn 101, Issue 11, 2003, Pages 4305-4312

  Andersson, Goran ^b   Illigens, Ben M W ^b   Johnson, Kevin W ^b   Caiderhead, David ^b   LeGuern, Christian ^b   Benichou, Gilles ^b   White Scharf, Mary E ^b   Down, Julian D ^a  

^a BioTransplant Inc   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; GREEN FLUORESCENT PROTEIN; TREOSULFAN; PHOTOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC SYSTEM; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN GRAFT; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; SKIN TRANSPLANTATION; TRANSGENE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; BUSULFAN; GENE THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; GREEN FLUORESCENT PROTEINS; IMMUNE TOLERANCE; LUMINESCENT PROTEINS; MICE; MICE, INBRED C57BL; SKIN TRANSPLANTATION; TRANSDUCTION, GENETIC; TRANSGENES; TRANSPLANTATION CONDITIONING;

EID: 0037804775     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1649     Document Type: Article

References (48)

1. Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genomics Hum Genet. 2001;2:177-211.
2. Heim DA, Hanazono Y, Giri N, et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther. 2000;1:533-544.
3. Berger C, Huang mL, Gough M, Greenberg PD, Riddell SR, Kiem H. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol. 2001;75:799-808.
4. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
5. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther. 1998;9:2121-2133.
6. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2:545-550.
7. Lutzko C, Kruth S, Abrams-Ogg AC, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood. 1999;93:1895-1905.
8. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther. 1999;10:1773-1781.
9. Stripecke R, Carmen Villacres M, Skelton D, et al. Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 1999;6:1305-1312.
10. d-restricted CTL epitope. Gene Ther. 2000;7:2036-2040.
11. + hematopoietic cells. Blood. 2001;97:1951-1959.
12. Wekerie T, Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med. 2001;52:353-370.
13. Sachs DH, Smith CV, Emery DW, et al. Induction of specific tolerance to MHC-disparate allografts through genetic engineering. Exp Nephrol. 1993;1:128-133.
14. Sykes M, Sachs DH, Nienhuis AW, Pearson DA, Moulton AD, Bodine DM. Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogeneic major histocompatibility complex gene. Transplantation. 1993;55:197-202.
15. Sonntag KC, Emery DW, Yasumoto A, et al. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest. 2001;107:65-71.
16. Fry JW, Morris PJ, Wood KJ. Adenoviral transfer of a single donor-specific MHC class I gene to recipient bone marrow cells can induce specific immunological unresponsiveness in vivo. Gene Ther. 2002;9:220-226.
17. Bagley J, Tian C, Sachs DH, Iacomini J. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood. 2002;99:4394-4399.
18. Okabe M, Ikawa M, Kominami K, et al. "Green mice" as a source of ubiquitous green cells. FEBS Lett. 1997;407:313-319.
19. Kawakami N, Sakane N, Nishizawa F, et al. Green fluorescent protein-transgenic mice: immune functions and their application to studies of lymphocyte development. Immunol Lett. 1999;70:165-171.
20. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219-244.
21. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8:145-154.
22. Ploemacher RE, Westerhof GR, Blokland I, Baumgart J, Down JD. Treosulfan as an alternative conditioning agent in bone marrow transplantation [abstract]. Bone Marrow Transplant. 2000;25(suppl 1):421.
23. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med. 1989;169:493-502.
24. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol. 1999;162:352-358.
25. Matesic D, Lehmann PV, Heeger PS. High-resolution characterization of cytokine-producing alloreactivity in naive and allograft-primed mice. Transplantation. 1998;65:906-914
26. Adams AB, Durham MM, Kean L, et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol. 2001;167:1103-1111.
27. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature. 1984;307:168-170.
28. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
29. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. N Engl J Med. 2000;343:802-803.
30. Denaro M, Morgan P, Patience P, et al. Induction of immunological tolerance towards EGFP transgenic skin grafts in recipients of EGFP-transduced bone marrow [abstract]. Blood. 2001;98: S214.
31. Stewart FM, Crittenden RB, Lowry PA, et al. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood, 1993;81:2566-2571.
32. van Os R, Down JD. Murine models of bone-marrow transplant conditioning. In: Teicher BA, ed. Tumor models in cancer research. Totowa, NJ: Humana Press; 2001:381-405.
33. Down JD, Ploemacher RE. Transient and permanent engraftment potential of murine hematopoletic stem cell subsets: differential effects of host conditioning with gamma radiation and cytotoxic drugs. Exp Hematol. 1993;21:913-921.
34. Westerhof GR, Ploemacher RE, Boudewijn A, et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res. 2000;60:5470-5478.
35. Leong LY, Qin S, Cobbold SP, Waldmann H. Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression. Eur J Immunol. 1992;22:2825-2830.
36. de Vries-van der Zwan A, van der Pol MA, de Waal LP, Boog CJ. An alternative conditioning regimen for induction of specific skin graft tolerance across full major histocompatibility complex barriers. Transpl Immunol. 1998;6:147-151.
37. Down JD, Johnson KW, Morgan PG, et al. Varying levels of MHC-mismatched donor-type chimerism and induction of immunological tolerance following different non-myeloablative transplant conditioning regimens [abstract]. Blood. 2000;96: S172-S173.
38. van Os R, Sheridan TM, Robinson S, Drukteinis D, Ferrara JL, Mauch PM. Immunogenicity of Ly5 (CD45)-antigens hampers long-term engraftment following minimal conditioning in a murine bone marrow transplantation model. Stem Cells. 2001;19:80-87.
39. Kang E, Giri N, Wu T, et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther. 2001;12:1663-1672.
40. Rosenzweig M, MacVittie TJ, Harper D, et al. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood. 1999;94:2271-2286.
41. Huhn RD, Tisdale JF, Agricola B, Metzger ME, Donahue RE, Dunbar CE. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther. 1999;10:1783-1790.
42. Vremec D, Zorbas M, Scollay R, et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med. 1992;176:47-58.
43. + dendritic cells prolong the survival of vascularized heart allografts. J Immunol. 2002;168:143-154.
44. Belz GT, Behrens GM, Smith CM, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med. 2002;196:1099-1104.
45. Denaro M, Oldmixon B, Patience C, Andersson G, Down J. EGFP-transduced EL-4 cells form tumors in C57BL/6 mice [letter]. Gene Ther. 2001;8:1814-1815.
46. Skelton D, Satake N, Kohn DB. The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice [letter]. Gene Ther. 2001;8:1813-1814.
47. rd Annual Meeting of the American Society of Hematology; December 7-11, 2001; Orlando, FL. Abstract 5022.
48. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410-2413.